HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- trifluoromethyl- 9- (2- fluorophenylmethyl)- N- methyladenine

a PDE4 inhibitor; structure in first source

Also Known As:

2-TFMe-9-FPhMe-MA; NCS 613

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Adenine: 2120
        2-trifluoromethyl-9-(2-fluorophenylmethyl)-N-methyladenine: 4

Experts

1.	Lugnier, Claire: 4 articles (01/2021 - 10/2011)
2.	Keravis, Thérèse: 3 articles (01/2021 - 01/2012)
3.	Yougbare, Issaka: 3 articles (01/2021 - 10/2011)
4.	Morin, Caroline: 2 articles (01/2020 - 10/2011)
5.	Rousseau, Eric: 2 articles (01/2020 - 10/2011)
6.	Abusnina, Abdurazzag: 1 article (01/2020)
7.	Belemnaba, Lazare: 1 article (01/2020)
8.	Senouvo, Yannick F: 1 article (01/2020)
9.	Bourguignon, Jean-Jacques: 1 article (01/2012)
10.	Gazi, Lucien: 1 article (01/2012)

Related Diseases

1.	Pneumonia (Pneumonitis) 10/01/2011 - "The aim of the present study was to investigate the role of the cyclic phosphodiesterase type 4 (PDE4) in human lung and to determine the effects of NCS 613, a new PDE4 inhibitor, on lung inflammation and bronchial hyperresponsiveness. " 10/01/2011 - "In conclusion, specific PDE4 inhibitors, such as NCS 613, may represent an alternative and isoform-specific approach toward reducing human lung inflammation and airway overreactivity."
2.	Adenocarcinoma of Lung 01/01/2020 - "An IC50 value of 8.5 μM was determined for NCS 613 on anti-proliferative properties while ERK1/2 signaling was down-regulated in A549 cells and lung adenocarcinoma explants. " 01/01/2020 - "The aim of this study was to investigate the anti-inflammatory and anti-proliferative effects of NCS 613, a specific PDE4 inhibitor, on TNFα-treated human lung adenocarcinoma cell line (A549) and on human lung adenocarcinoma explants. " 01/01/2020 - "NCS 613, a Potent PDE4 Inhibitor, Displays Anti-Inflammatory and Anti-Proliferative Properties on A549 Lung Epithelial Cells and Human Lung Adenocarcinoma Explants."
3.	Inflammation (Inflammations) 01/01/2020 - "It suggests that PDE4 inhibition by NCS 613 represent potential and interesting strategy for therapeutic intervention in tackling chronic inflammation and cell proliferation." 10/01/2011 - "Pharmacological treatments with NCS 613 significantly decreased PDE4 activity and reduced IκBα degradation in cultured parenchyma, both of which are usually correlated with a lower inflammation status. " 01/01/2021 - "NCS 613 overcomes disease progression in lupus prone mice by improving wellbeing and decreasing inflammation in treated mice. " 01/01/2021 - "NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL/lpr lupus- prone mice."
4.	Disease Progression 01/01/2021 - "NCS 613 overcomes disease progression in lupus prone mice by improving wellbeing and decreasing inflammation in treated mice. " 01/01/2012 - "Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor."
5.	Proteinuria 01/01/2012 - "Furthermore, it showed that the most potent and selective PDE4 inhibitor NCS 613 is also the most effective molecule in decreasing proteinuria and increasing survival rate of MRL/lpr mice. "

Related Drugs and Biologics

1.	Phosphodiesterase 4 Inhibitors
2.	Phosphoric Diester Hydrolases (Phosphodiesterases)
3.	Protein Isoforms (Isoforms)
4.	Cyclic Nucleotides
5.	Antigen-Antibody Complex (Immune Complex)